Search results for "clinical studies"

showing 10 items of 34 documents

Hepatitis B surface antigen presentation and HLA-DRB1*– lessons from twins and peptide binding studies

2005

Summary The aim of this study was to investigate the underlying mechanisms of the genetic association between certain HLA-DRB1* alleles and the immune response to HBsAg vaccination. Therefore, HBsAg peptide binding to HLA-DR molecules was measured in vitro by peptide binding ELISAs. Additionally, HBsAg-specific T cell reaction and cytokine profile of immune response were analysed ex vivo in ELISPOT assays and DR-restriction of T-cell proliferative responses was investigated with HBsAg specific T cell clones. In addition, we compared HBsAg specific T cell responses of 24 monozygotic and 3 dizygotic twin pairs after HBsAg vaccination. Our results showed that the peptide binding assays did not…

AdultHBsAgAdolescentT cellDizygotic twinMolecular Sequence DataImmunologyAntigen presentationAntibody AffinityTwinsMonozygotic twinEnzyme-Linked Immunosorbent AssayPeptide bindingLymphocyte ActivationMajor histocompatibility complexBinding CompetitiveClinical StudiesmedicineHLA-DRHumansImmunology and AllergyHepatitis B VaccinesAmino Acid SequenceCells CulturedAgedAntigen PresentationHepatitis B Surface Antigensbiologyvirus diseasesDendritic CellsHLA-DR AntigensMiddle AgedTh1 CellsVirologydigestive system diseasesmedicine.anatomical_structureImmunologybiology.proteinCytokinesHLA-DRB1 ChainsClinical and Experimental Immunology
researchProduct

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

2015

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in …

Research designPathologyData baseResearch methodologyElectronic medical recordDiseaseReviewProceduresTreatment responseClinical trials; Rare cancers; Research methodology; Clinical Studies as Topic; Humans; Neoplasms; Rare Diseases; Research Design; Hematology; OncologyClinical trialsNeoplasmsReimbursementPriority journaleducation.field_of_studyClinical Studies as TopicClinical studies as topicHematologyRare diseasesEuropeOncologyResearch designResearch DesignClinical decision makingHumanmedicine.medical_specialtyPractice guidelineCase findingPopulationHealth care qualityReviewsCancer researchClinical studyRare DiseasesSDG 3 - Good Health and Well-beingConceptual frameworkmedicineHumansRare cancersTumor markerIntensive care medicineeducationAntineoplastic activityFlexibility (engineering)Surrogate endpointbusiness.industryMethodologyRare cancerStudy designCancer survivalReimbursementClinical trialClinical trials; Rare cancers; Research methodology; Hematology; OncologyPatient informationClinical effectivenessPosition paperNeoplasmbusinessRare disease
researchProduct

Interventions for reducing loneliness: An umbrella review of intervention studies

2020

Loneliness is a common phenomenon associated with several negative health outcomes. Current knowledge regarding interventions for reducing loneliness in randomised controlled trials (RCTs) is conflicting. The aim of the present work is to provide an overview of interventions to reduce loneliness, using an umbrella review of previously published systematic reviews and meta-analyses. We searched major databases from database inception to 31 March 2020 for RCTs comparing active versus non-active interventions for reducing loneliness. For each intervention, random-effects summary effect size and 95% confidence intervals (CIs) were calculated. For significant outcomes (p-value < 0.05), the GR…

medicine.medical_specialtyMindfulnessSociology and Political Sciencebusiness.industryLonelinessHealth PolicyClinical Studies as TopicPublic Health Environmental and Occupational HealthPsychological interventionLonelinesslaw.inventionSocial supportSystematic reviewRandomized controlled triallawMeta-analysisloneliness meta-analysis randomised controlled trial social umbrella reviewmedicinePhysical therapyHumansmedicine.symptombusinessMindfulnessSocial Sciences (miscellaneous)Social cognitive theoryHealth & Social Care in the Community
researchProduct

Pre-Clinical Studies with D-Penicillamine as a Novel Pharmacological Strategy to Treat Alcoholism: Updated Evidences

2017

Ethanol, as other drugs of abuse, is able to activate the ventral tegmental area dopamine (VTA-DA) neurons leading to positively motivational alcohol-seeking behavior and use, and, ultimately to ethanol addiction. In the last decades, the involvement of brain-derived acetaldehyde (ACD) in the ethanol actions in the mesolimbic pathway has been widely demonstrated. Consistent published results have provided a mechanistic support to the use of ACD inactivating agents to block the motivational and reinforcing properties of ethanol. Hence, in the last years, several pre-clinical studies have been performed in order to analyze the effects of the sequestering ACD agents in the prevention of ethano…

Drugmedia_common.quotation_subjectMini ReviewCognitive NeurosciencePsychological interventionMesolimbic pathwayPharmacologyBioinformaticsRelapse preventionethanol relapse prevention03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineDopamineIntervention (counseling)acetaldehyde sequestering agentMedicinevoluntary alcohol consumptionpre-clinical studiesmedia_commonbusiness.industryAddictionD-penicillamine030227 psychiatryVentral tegmental areamedicine.anatomical_structureNeuropsychology and Physiological Psychologybusiness030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Behavioral Neuroscience
researchProduct

Acute Postcataract Surgery Endophthalmitis Due to Streptococcus Species Differs From Endophthalmitis Due to Staphylococcus Species at Presentation

2009

Purpose: : To correlate the presenting clinical ophthalmic features with the bacterial identification in 100 patients with acute post catarcat endophthalmitis enrolled in the FRench Instutionnal ENdophthalmitis Study (FRIENDS).Methods: : Demographic data, past medical history and initial eye examination were recorded in a standardized form in 100 patients with acute endophthalmitis after cataract extraction (< 6 weeks) in a prospective multicenter study. Relationship between microbiological identification (using conventional cultures and panbacterial PCR) and clinical factors at baseline was studied using univariate (ANOVA).Results: : 100 patients were hospitalized for endophthalmitis treat…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyendophthalmitis[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organsmicrobial pathogenesis: clinical studiesbacterial disease
researchProduct

Erratum: Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer

2005

Hormonal therapy is the preferred systemic treatment for recurrent or metastatic, post-menopausal hormone-receptor-positive breast cancer. Previous studies have shown that there is no cross-resistance between exemestane and reversible aromatase inhibitors. Exposure to hormonal therapy does not hamper later response to chemotherapy. Patients with locally advanced or metastatic, hormonal receptor positive or unknown, breast cancer were treated with oral anastrozole, until disease progression, followed by oral exemestane until new evidence of disease progression. The primary end point of the study was clinical benefit, defined as the sum of complete responses (CR), partial responses (PR) and >…

AdultOncologyCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAntineoplastic Agents Hormonalmedicine.medical_treatmentAdministration OralPhases of clinical researchAnastrozoleBreast NeoplasmsAnastrozoleMetastasischemistry.chemical_compoundbreast cancerBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsNitrilesClinical StudiesHumansMedicineAgedGynecologybusiness.industrysequential hormonal therapyCancerMiddle AgedTriazolesmedicine.diseaseMetastatic breast cancerAndrostadienesOncologychemistryChemotherapy AdjuvantHormonal therapyFemaleHormone therapyCorrigendumbusinessmedicine.drugBritish Journal of Cancer
researchProduct

Myoglobin, expressed in brown adipose tissue of mice, regulates the content and activity of mitochondria and lipid droplets

2021

Abstract The identification of novel physiological regulators that stimulate energy expenditure through brown adipose tissue (BAT) activity in substrate catalysis is of utmost importance to understand and treat metabolic diseases. Myoglobin (MB), known to store or transport oxygen in heart and skeletal muscles, has recently been found to bind fatty acids with physiological constants in its oxygenated form (i.e., MBO2). Here, we investigated the in vivo effect of MB expression on BAT activity. In particular, we studied mitochondrial function and lipid metabolism as essential determinants of energy expenditure in this tissue. We show in a MB-null (MBko) mouse model that MB expression in BAT i…

PalmitatesOxidative phosphorylationMitochondrion1307 Cell BiologyMiceAdipose Tissue BrownLipid dropletBrown adipose tissueRespiration1312 Molecular BiologymedicineAnimalsHumansPPAR alpha11434 Center for Clinical StudiesMuscle SkeletalMolecular BiologyUncoupling Protein 1Mice KnockoutMyoglobinChemistryProteinsThermogenesisLipid metabolismLipid DropletsCell BiologyMetabolism10081 Institute of Veterinary PhysiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaCell biologyOxygenDisease Models AnimalAdipocytes Brownmedicine.anatomical_structure10076 Center for Integrative Human Physiology570 Life sciences; biologyApoptosis Regulatory ProteinsEnergy MetabolismThermogenesisBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
researchProduct

A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma

2006

Potential synergistic interaction between gemcitabine (GEM) and epirubicin (EPI) in pancreatic cancer have been described previously. The maximum-tolerated dose in this trial was GEM 1000 mg m(-2) and EPI 45 mg m(-2). Median time to progression was 5.1 months and median survival time 7.4 months. This combination appears well tolerated and shows promising clinical activity.

OncologyAdultMaleCancer Researchmedicine.medical_specialtyPancreatic diseaseendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentpancreatic cancerAntineoplastic AgentschemotherapyAntimetaboliteDeoxycytidinechemistry.chemical_compoundHemoglobinsLeukocyte CountInternal medicinePancreatic cancerClinical StudiesmedicineHumansIn patientAgedNeoplasm StagingChemotherapyDose-Response Relationship Drugbusiness.industryPlatelet CountgemcitabineMiddle Agedmedicine.diseaseepirubicinGemcitabineSurgeryPancreatic NeoplasmsOncologychemistryDeoxycytidineFemalebusinessEpirubicinmedicine.drugBritish Journal of Cancer
researchProduct

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a p…

2008

This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal cancer patients progressing to at least one previous chemotherapy line. A total of 40 patients were treated between November 2005 and November 2007 with irinotecan 180 mg m−2 and cetuximab 500 mg m−2 q2w (every 2 weeks), in every 21-day cycles, until unacceptable toxicity or progressive disease. An overall response rate of 22.5% was obtained (two complete and seven partial responses). The disease control rate was 60%. The time to progression was 3.4 months and the overall survival was 8 months. The toxicity compared very favourably to weekly cetuximab combi…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsClinical StudiesmedicineHumansProspective StudiesNeoplasm MetastasisAdverse effectAgedChemotherapyCetuximabbusiness.industrymetastatic colorectal cancerbiweekly scheduleAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryClinical trialIrinotecanRegimenOncologyCamptothecinFemaleColorectal NeoplasmsbusinessProgressive diseasemedicine.drugBritish Journal of Cancer
researchProduct

The Potential Use of Resveratrol for Cancer Prevention.

2019

In addition to the traditional treatments of cancer and cancer prevention, the use of natural compounds, especially those found in food, should be considered. To clarify if resveratrol has the potential for cancer prevention and the possibility of use in therapy, the following must be taken into account: data from epidemiology, clinical protocol (case and control), preclinical studies (lab animals), use of established cell lines as models of cancer cells, test tube assays (enzymes activities), and requirements of nanotechnologies in order to discover new drugs to fight cancer. From this perspective and future expected advances, more information is needed such as improved efficacy, methods o…

medicine.medical_treatmentDrug Evaluation PreclinicalPharmaceutical ScienceReviewResveratrolresveratrolBioinformaticsChemopreventionAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinepreventionNeoplasmsDrug DiscoverymedicineAnimalsHumanscancerPhysical and Theoretical ChemistrySensitization030304 developmental biology0303 health sciencesmechanismsCancer preventionbusiness.industryOrganic ChemistryClinical Studies as TopicCancerDisease Managementmedicine.diseaseAntineoplastic Agents PhytogenicBioavailabilitymedicine.anatomical_structurechemistryChemistry (miscellaneous)030220 oncology & carcinogenesisapproach strategiesCancer cellMolecular MedicineDisease Susceptibilitybusinessinnovative formulationsAdjuvantSignal TransductionMolecules (Basel, Switzerland)
researchProduct